Duval/CIBMTR Score for Acute Myelogenous Leukemia (AML) Survival
Código: 10040 · duval_cibmtr_score_acute_myelogenous_leukemia_aml_survival
Predicts overall survival in AML patients with relapsed/refractory disease undergoing myeloablative transplant.
Ver respuesta cruda
Referencias
Original/Primary Reference
- Duval M, Klein JP, He W, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28(23):3730-8. ↗
Other References
- Armand P, Kim HT, Cutler CS, et al. A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008;14(1):28-35. ↗
- Sorror ML, Storer BE, Fathi AT, et al. Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. JAMA Oncol. 2017;3(12):1675-1682. ↗
Validation
- Todisco E, Ciceri F, Oldani E, et al. The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo. Leukemia. 2013;27(10):2086-91. ↗